CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
Rituximab + ACVBP regimen plus Pegfilgrastim +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00169143
NCT00169143Phase 2Completed
CompareCT.gov

Study of R-ACVBP Regimen Supported by Pegfilgrastim in Previously Untreated Patients Aged From 18 to 60 Years With High-Risk Diffuse Large B-Cell Lymphoma (Age-adjusted Ipi >or= 2)

Lymphoma Study Association·interventional·Posted Sep 15, 2005·Updated Aug 23, 2018

In Brief

A Phase 2 clinical trial evaluating Rituximab + ACVBP regimen plus Pegfilgrastim and Autologous stem cell transplant for Untreated CD20-positive Large B-cell Lymphoma. Completed, across 6 sites.

Detailed Summary

Evaluation of the efficacy of a single injection of Pegfilgrastim (6mg) administered at day 3 of each cycle of R-ACVBP regimen during 4 cycles in patients with CD20+ diffuse large B-cell lymphoma presenting at least 2 adverse prognostic factor of the age-adjusted international prognostic index (Aa-IPI).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUntreated CD20-positive Large B-cell Lymphoma
CountriesFrance
CollaboratorsAmgen

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 15, 2005
Enrollment StartMay 1, 2004
Primary CompletionJan 1, 2007
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 20.8 years ago

Interventions

Rituximab + ACVBP regimen plus Pegfilgrastimdrug

Autologous stem cell transplantprocedure